Literature DB >> 15389588

Animal models for the study of adenosine receptor function.

R Yaar1, M R Jones, J-F Chen, Katya Ravid.   

Abstract

Adenosine receptors represent a family of G-protein coupled receptors that are ubiquitously expressed in a wide variety of tissues. This family contains four receptor subtypes: A1 and A3, which mediate inhibition of adenylyl cyclase; and A2a and A2b, which mediate stimulation of this enzyme. Currently, all receptor subtypes have been genetically deleted in mouse models except for the A2b adenosine receptor, and some have been overexpressed in selective tissues of transgenic mice. Studies involving these transgenic mice indicated that receptor levels are rate limiting, as effects were amplified upon increases in receptor level. The knockout models pointed to clusters of activities related to the physiologies of the cardiovascular and the nervous systems, which are either reduced or enhanced upon specific receptor deletion. Interestingly, the trend of effects on these systems is similar in the A1 and A3 adenosine receptor knockout mice and opposite to the effects observed in the A2a adenosine receptor knockout model. This review summarizes in vitro studies on pathways affected by each adenosine receptor, and primarily focuses on the above in vivo models generated to investigate the physiologic role of adenosine receptors. Furthermore, it illustrates the need for multiple adenosine receptor subtype deficiency studies in mice and the deletion of the A2b subtype. 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15389588     DOI: 10.1002/jcp.20138

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  48 in total

1.  Inhibition of vascular ectonucleotidase activities by the pro-drugs ticlopidine and clopidogrel favours platelet aggregation.

Authors:  Joanna Lecka; Manjit Singh Rana; Jean Sévigny
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

2.  Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.

Authors:  Artem Melman; Zhan-Guo Gao; Deepmala Kumar; Tina C Wan; Elizabeth Gizewski; John A Auchampach; Kenneth A Jacobson
Journal:  Bioorg Med Chem Lett       Date:  2008-04-04       Impact factor: 2.823

3.  Internalization and desensitization of adenosine receptors.

Authors:  Elisabeth C Klaasse; Adriaan P Ijzerman; Willem J de Grip; Margot W Beukers
Journal:  Purinergic Signal       Date:  2007-11-13       Impact factor: 3.765

4.  Microinjection of adenosine into the hypothalamic ventrolateral preoptic area enhances wakefulness via the A1 receptor in rats.

Authors:  Jin Zhang; Dou Yin; Fang Wu; Gongliang Zhang; Chuanwei Jiang; Zhen Li; Liecheng Wang; Kai Wang
Journal:  Neurochem Res       Date:  2013-05-09       Impact factor: 3.996

Review 5.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

Review 6.  Adenosine: an immune modulator of inflammatory bowel diseases.

Authors:  Jeff Huaqing Ye; Vazhaikkurichi M Rajendran
Journal:  World J Gastroenterol       Date:  2009-09-28       Impact factor: 5.742

7.  Adenosine mediated desensitization of cAMP signaling enhances T-cell responses.

Authors:  Ailian Yang; Ashley D Mucsi; Melanie D Desrosiers; Jiang-Fan Chen; Jürgen B Schnermann; Michael R Blackburn; Yan Shi
Journal:  Eur J Immunol       Date:  2010-02       Impact factor: 5.532

8.  Adenosine A2A receptor signaling regulation of cardiac NADPH oxidase activity.

Authors:  David Ribé; David Sawbridge; Sapna Thakur; Martin Hussey; Catherine Ledent; Ian Kitchen; Susanna Hourani; Jian-Mei Li
Journal:  Free Radic Biol Med       Date:  2008-01-05       Impact factor: 7.376

9.  Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Authors:  Dale O Kiesewetter; Lixin Lang; Ying Ma; Abesh Kumar Bhattacharjee; Zhan-Guo Gao; Bhalchandra V Joshi; Artem Melman; Sonia de Castro; Kenneth A Jacobson
Journal:  Nucl Med Biol       Date:  2009-01       Impact factor: 2.408

10.  Recent improvements in the development of A(2B) adenosine receptor agonists.

Authors:  Pier Giovanni Baraldi; Mojgan Aghazadeh Tabrizi; Francesca Fruttarolo; Romeo Romagnoli; Delia Preti
Journal:  Purinergic Signal       Date:  2009-01-31       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.